Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure
Guillermo Torre‐Amione(Cornell University), Isaac Kobrin(Actelion (Switzerland)), Maurizio Rainisio(Actelion (Switzerland)), John R. Teerlink(San Francisco VA Medical Center), Wilson S. Colucci(Cornell University), Uri Elkayam(University of Southern California), Aline Frey(Actelion (Switzerland)), Gad Cotter(Assaf Harofeh Medical Center), Craig M. Pratt(Baylor College of Medicine), James B. Young, Karl Stangl(Humboldt-Universität zu Berlin), Basil S. Lewis(Carmel Medical Center)
Cited by 119
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Contemporary Definitions and Classification of the Cardiomyopathies
|Circulation|2006|3.4k
Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
|The Lancet|1996|1.4k
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure
|Circulation|2004|1.2k
Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure
|New England Journal of Medicine|2000|908